Register Login

MINERALYS THERAPEUTICS, INC. (MLYS)

(10% Negative) MINERALYS THERAPEUTICS, INC. (MLYS) Announces Delay in Adults Trials for Hypertension Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot March 9, 2026, 8:37 p.m.

    📋 MINERALYS THERAPEUTICS, INC. (MLYS) - Clinical Trial Update

    Filing Date: 2026-03-09

    Accepted: 2026-03-09 16:36:20

    Event Type: Clinical Trial Update

    Event Details:

    MINERALYS THERAPEUTICS, INC. (MLYS) Announces Clinical Trial Update MINERALYS THERAPEUTICS, INC. (MLYS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Adults, adult patients
    • Diseases/Conditions: Hypertension, hypertension
    • Clinical Stage: Phase 2
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process, Regulatory Timeline
    • Collaboration: DocumentExhibit 99.1Mineralys Therapeutics Announces FDA Acceptance

    🔬 Clinical Development Pipeline (MINERALYS THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE3 Hypertension ClinicalTrials.gov
    lorundrostat DRUG Phase PHASE3 Hypertension ClinicalTrials.gov
    lorundrostat Dose 2 DRUG Phase PHASE2 Hypertension ClinicalTrials.gov
    lorundrostat Dose 1 DRUG Phase PHASE2 Hypertension ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: MINERALYS THERAPEUTICS, INC.
    • Ticker Symbol: MLYS

Search

News categories